Differential regulation of NAB corepressor genes in Schwann cells
Rajini Srinivasan1, Sung-Wook Jang2, Rebecca M Ward1, Shrikesh Sachdev3, Toshihiko Ezashi4 and John Svaren*1

Address: 1Department of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI, USA, 2Program in Cellular and Molecular Biology, University of Wisconsin-Madison, Madison, WI, USA, 3Department of Biochemistry, University of Missouri-Columbia, Columbia, MO, USA and 4Department of Animal Sciences, University of Missouri-Columbia, Columbia, MO, USA

Email: Rajini Srinivasan - rsrinivasan@wisc.edu; Sung-Wook Jang - sungwookjang@wisc.edu; Rebecca M Ward - rebeccamward@hotmail.com; Shrikesh Sachdev - sachdevs@missouri.edu; Toshihiko Ezashi - EzashiT@missouri.edu; John Svaren* - jpsvaren@wisc.edu

* Corresponding author

Abstract

**Background:** Myelination of peripheral nerves by Schwann cells requires not only the Egr2/Krox-20 transactivator, but also the NGFI-A/Egr-binding (NAB) corepressors, which modulate activity of Egr2. Previous work has shown that axon-dependent expression of Egr2 is mediated by neuregulin stimulation, and NAB corepressors are co-regulated with Egr2 expression in peripheral nerve development. NAB corepressors have also been implicated in macrophage development, cardiac hypertrophy, prostate carcinogenesis, and feedback regulation involved in hindbrain development.

**Results:** To test the mechanism of NAB regulation in Schwann cells, transfection assays revealed that both Nab1 and Nab2 promoters are activated by Egr2 expression. Furthermore, direct binding of Egr2 at these promoters was demonstrated in vivo by chromatin immunoprecipitation analysis of myelinating sciatic nerve, and binding of Egr2 to the Nab2 promoter was stimulated by neuregulin in primary Schwann cells. Although Egr2 expression activates the Nab2 promoter more highly than Nab1, we surprisingly found that only Nab1 – but not Nab2 – expression levels were reduced in sciatic nerve from Egr2 null mice. Analysis of the Nab2 promoter showed that it is also activated by ETS proteins (Ets2 and Etv1/ER81) and is bound by Ets2 in vivo.

**Conclusion:** Overall, these results indicate that induction of Nab2 expression in Schwann cells involves not only Egr2, but also ETS proteins that are activated by neuregulin stimulation. Although Nab1 and Nab2 play partially redundant roles, regulation of Nab2 expression by ETS factors explains several observations regarding regulation of NAB genes. Finally, these data suggest that NAB proteins are not only feedback inhibitors of Egr2, but rather that co-induction of Egr2 and NAB genes is involved in forming an Egr2/NAB complex that is crucial for regulation of gene expression.

**Background**

Members of the EGR (early growth response) family of transactivators fulfill critical roles in diverse systems, including nervous system development, bone formation, and fertility. Transcriptional activity of three EGR family members (Egr1/NGFI-A, Egr2/Krox20, and Egr3) is regu-
lated by interaction with the NAB (NGFI-A/EGR binding) family of transcriptional corepressors. The Nab1 protein was first identified by screening a yeast two-hybrid library for proteins that interact with a repressive domain within Egr1 [1], and Nab2 was subsequently found to share similar properties [2]. Both Nab1 and Nab2 can bind to a conserved domain in Egr1, Egr2 and Egr3. NAB proteins repress activation of several EGR target promoters [3-5], and the repression mechanism involves interaction with the CHD4 subunit of the Nucleosome Remodeling and Deacetylase (NuRD) complex [6].

The most severe phenotypes caused by loss of EGR function have been found in mice lacking the Egr2/Krox20 gene (hereafter referred to as Egr2). Characterization of these mice revealed three principal defects: 1) defective hindbrain segmentation with the loss of rhombomeres r3 and r5 [7,8], 2) defective bone formation [9], and 3) failure of Schwann cells to myelinate peripheral nerves [10-12]. Target genes regulated by Egr2 in Schwann cells include myelin genes such as Myelin Protein Zero and Myelin-associated glycoprotein [10-15]. As a consequence, most mice with a homozygous Egr2 disruption die shortly after birth, although some show a hypomorphic Egr2 allele survive somewhat longer [11].

Because of the myelination defect in peripheral nerves of Egr2 knockout mice, several groups have screened human patients with peripheral neuropathies for mutations in the EGR2 gene. Mutations in EGR2 have been identified in several patients with myelin disorders, such as Charcot-Marie-Tooth (CMT) disease, Dejerine-Sottas Syndrome, and Congenital Hypomyelinating Neuropathy [16-20]. Most of the neuropathy-associated mutations occur within the zinc fingers of EGR2 and prevent DNA-binding [21]. However, one of the EGR2 mutations associated with a very severe congenital hypomyelinating neuropathy [I268N, [16]] prevents binding of EGR2 to NAB corepressors [21]. The importance of NAB corepressors to the regulation of peripheral nerve myelination by Egr2 was recently confirmed by the demonstration that a double knockout of the Nab1/Nab2 genes results in a phenotype very similar to that of the Egr2 knockout: early lethality and peripheral neuropathy resulting from arrested myelination [22]. Moreover, NAB genes have been implicated in several other physiological processes, including macrophage development, cardiac hypertrophy, prostate carcinogenesis, and feedback regulation involved in hindbrain development [23-26].

As critical regulators of peripheral myelination, it is important to probe the mechanism of NAB regulation. Recent work has shown that Nab1 and Nab2 are induced by neuregulin signaling [22]. Neuregulin signaling plays an extremely important role in axon-derived signals for Schwann cell myelination [27-35]. Moreover, Egr2 and NAB expression appear to be closely linked, as Nab1 and Nab2 are co-regulated with Egr2 after nerve crush injury, and both corepressors are induced by ectopic Egr2 expression in cultured Schwann cells [22,36,37]. However, direct regulation of Nab1 and Nab2 by Egr2 has not been demonstrated in vivo. The following data demonstrate direct regulation of NAB expression by Egr2 in myelinating sciatic nerve, and indicate that other neuregulin-regulated pathways are specifically involved in inducing Nab2 expression.

Results

Induction of Nab promoters by Egr2

Sequence analysis of the Nab1 and Nab2 promoters identified several conserved motifs that resemble Egr2 binding sites [22]. To test whether these sites bind Egr2, the mouse Nab1 and Nab2 promoters were analyzed by DNase I footprinting. In the presence of recombinant Egr2, there were strongly protected regions encompassing three previously identified sites in the Nab2 promoter, as well as some weaker protections (Figure 1A). Interestingly, previous analysis of Egr2 site specificity indicated a strong preference for T in the 4th position of the consensus sequence [GCGTGGCGC, [38]], and each of the three strongly protected sites have a T in the 4th base. A similar analysis of the mouse Nab1 promoter (Figure 1B) confirmed binding of Egr2 to the conserved binding sites identified previously [22]. The strong binding site at the 3' end of the mouse Nab2 promoter corresponds to a site of phorbol ester-induced Egr1 binding in a recent analysis of the human NAB2 promoter using electrophoretic mobility shift assays [39].

To test the function of the Egr2 binding sites, fragments encompassing the conserved regions of the Nab1 and Nab2 promoters were fused to a luciferase reporter gene and transfected into JEG-3 cells, which exhibit a low level of expression of EGR proteins [40]. As shown in Figure 1C, expression of Egr2 activated the Nab1 promoter up to 15-fold, and the Nab2 reporter was increased 25-fold. Two of the Egr2 binding sites in the Nab2 promoter were mutated to determine how that would affect activation by Egr2. As shown in Figure 1, we still observed some residual activation of the promoter, but the induction was much less than observed with the wild type promoter. Previous work had indicated that Nab2 is more inducible by serum and neuregulin than Nab1 [2,22]. Moreover, the Nab2 promoter was more highly induced by Egr2 in the transfection experiments. However, this disparity is somewhat surprising, given that the Nab1 promoter contains more Egr2 binding sites than does Nab2.
Egr2 activates the Nab1 and Nab2 promoters. A) The plot shows percent identity of the human and mouse Nab2 loci upstream of the first exon. DNase I footprinting analysis of a 1000 bp fragment of the mouse Nab2 promoter in the presence of recombinant Egr2 protein revealed two footprinted regions (solid line) with some weaker protections (dotted lines). The footprinted regions correspond to three of the four previously identified conserved sites [filled circles, 22] that conform to the Egr2 consensus binding site. There was no apparent footprint over putative site #4 identified in previous sequence analysis of the Nab2 promoter [22] M = marker lane. B) A similar analysis of the mouse Nab1 promoter confirmed binding of Egr2 to the six previously identified conserved binding sites in the mouse Nab1 promoter [filled circles, 22]. C) JEG-3 cells were transfected with a luciferase reporter plasmid containing either the Nab1 or Nab2 promoter, and the indicated amounts of an Egr2 expression construct. The mutant Nab2 promoter contains mutations in the two upstream Egr2 binding sites. Egr2 binding sites are indicated by filled circles. The y-axis shows the fold activation normalized to the activity of the reporter alone. Means and standard deviations of three separate transfections are shown. Activation of both Nab1 and Nab2 promoters by 25 ng Egr2 (compared to control) was statistically significant (P <= 0.002).
Neuregulin stimulation increases Egr2 occupancy of the Nab1 and Nab2 promoters

In rat Schwann cells treated with neuregulin, there is a large induction of Egr2 (within 1 hour), followed by a delayed induction of Nab1 and Nab2, which peaks at two hours after neuregulin addition [22], with Nab2 being more highly induced than Nab1. To test if neuregulin stimulates direct binding of Egr2 to the NAB promoters, chromatin immunoprecipitation (ChIP) assays were used, in which formaldehyde is used to covalently crosslink DNA with any associated proteins and the proteins of interest are subsequently immunoprecipitated [14,41]. Primary rat Schwann cells were treated for 2 hours with neuregulin and then cross-linked with 1% formaldehyde. Sonicated chromatin was then immunoprecipitated with an Egr2 antibody or control IgG. An untreated culture of Schwann cells was also cross-linked and immunoprecipitated similarly. After crosslinks were reversed, purified DNA was analyzed by quantitative PCR using primer sets proximal to the Egr2 binding sites in the Nab1 and Nab2 promoters. As shown in Figure 2, binding of Egr2 to the Nab1 and Nab2 promoters was significantly stimulated upon treatment with neuregulin. Egr2 binding was not detected at an immunoglobulin promoter [IMG2A, which lacks Egr2 binding sites and is transcriptionally silent in Schwann cells, [14,41]] in either sample. Evidence for the specificity of the antibody used for ChIP analysis includes induction of Egr2 binding by neuregulin (Figure 2), and immunoblot analysis using this antibody reveals a band of the correct size (Figure 3). In addition, this antibody has been extensively tested with multiple negative control sites [6,14,41], and expression of dominant negative Egr2 (consisting of the DNA-binding domain of Egr2) reduces Egr2 binding in this assay (unpublished data). In parallel cultures, Nab2 mRNA was induced 11-fold upon treatment with neuregulin for 2 hours, consistent with previously published results [22].

Egr2 binds to the Nab1 and Nab2 promoters in myelinating sciatic nerve

We have recently employed ChIP analysis of myelinating sciatic nerve to test whether Egr2 directly regulates specific elements in vivo [6,14,41]. Egr2 expression increases concurrently with initiation of myelination in rat sciatic nerve within two weeks after birth [42], which is also observed in immunoblot analysis of Egr2 expression in P5 and P15 rat sciatic nerve (Figure 3). Therefore, freshly dissected sciatic nerves from rat pups at P10 (from pools of 5–13 pups) were minced in 1% formaldehyde after dissection. After immunoprecipitation of sonicated chromatin, quantitation of the ChIP assays demonstrated significant enrichment of Egr2 at both Nab1 and Nab2 promoters in rat sciatic nerve (Figure 3).

Figure 2

Neuregulin stimulates Egr2 binding to the Nab2 promoter in primary Schwann cells. Primary rat Schwann cells, untreated or exposed to neuregulin for 2 h, were analyzed by ChIP assay. Formaldehyde-crosslinked chromatin from the two cultures were immunoprecipitated with an antibody for Egr2 (filled bars) or purified control IgG (open bars). Percentage recovery relative to input was determined using quantitative PCR with primers designed for the Nab1, Nab2 and Immunoglobulin 2A (IMG2A) promoters. The horizontal lines above the promoter diagrams indicate the positions of the amplicons derived from the primer sets used for ChIP analysis. Means and standard deviations were calculated for duplicate measurements from two independent experiments.

Nab expression levels in peripheral nerve of Egr2-deficient mice

To independently test the regulation of NAB genes by Egr2 in vivo, we examined NAB expression levels in the Egr2/Krox20 knockout (Figure 4). In these mice, Schwann cells develop normally and associate with axons, but fail to initiate myelination of peripheral nerves [10]. The sciatic nerves of seventeen wild type and knockout animals at P7 were pooled, and the levels of Nab1 and Nab2 were determined by quantitative PCR. Previous analysis of these samples had indicated that expression of many myelin-associated Egr2 target genes are significantly reduced in the knockout nerves [14,41,43]. Consistent with the data from the transfection and ChIP assays, we observed a significant decrease in the expression of Nab1. A similar reduction in Nab1 expression was reported in mice with a hypomorphic allele of Egr2 [22]. In contrast, the expression level of Nab2 was not significantly different in mice containing the null allele of Egr2/Krox20.
Given the unexpected finding that the expression level of Nab2 was not lower in the absence of Egr2, the Nab2 promoter was screened for other transcription factor binding sites that could contribute to Nab2 expression, thereby compensating for the loss of Egr2 activation. Analysis of the Nab2 promoter revealed several putative binding sites for ETS transcription factors (diagrammed in Figure 6B). Interestingly, ETS proteins are regulated by neuregulin signaling [44-46]. In addition, previous studies have identified ETS transcription factors as playing an important role in autocrine and neuregulin-mediated survival of Schwann cells, and showed that several ETS genes, including Net/Elk3, Ets2, GABPα and Etv1/ER81, are expressed in E12 and newborn mouse peripheral nerve [47]. Ets2 and Etv1/ER81 (hereafter referred to as Etv1) were selected for further analysis as they were highly expressed in microarray analyses of mouse sciatic nerve [see 94246, 92927 probe sets in supplementary data of [48,49]].

Quantitative PCR analysis confirmed significant levels of Ets2 and Etv1 in mouse and rat sciatic nerves during peripheral nerve myelination (data not shown), and Western analysis (Figure 5A) showed that both Ets2 and Etv1 are developmentally increased in rat sciatic nerve at P15, compared to the P5 (early myelination) timepoint. Since Nab2 expression was unaffected in the Egr2 knockout, we assessed the expression levels of Ets2, Etv1, and Elk3 in Egr2 knockout nerves from P7 mice. Interestingly, Ets1 expression was previously shown to be elevated in sciatic nerve of Egr2-deficient mice [11], and Etv1 expression was somewhat higher in the Egr2 null mice compared to wild-type mice (Figure 5B). The presence of Ets2 and Etv1 in mouse and rat sciatic nerve during myelination [47-49], as well as in Egr2 null mice, suggest that ETS transcription factors could compensate in the absence of Egr2 to maintain Nab2 expression levels.

ETS proteins activate the Nab2 promoter
To test whether ETS proteins activate the Nab1 and Nab2 promoters, JEG3 cells were transfected with the Nab1 or Nab2 reporters described above, along with expression vectors for Ets2 and Etv1. Western analysis revealed that Ets2 and Etv1 expression in JEG3 cells is much lower than found in the S16Y Schwann cell line (Figure 6A). The
Nab2 promoter was significantly induced by Ets2 and Etv1 expression, and this induction was further potentiated by coexpression of Egr2 (Figure 6B). A dominant-negative ETS construct [consisting of the DNA-binding domain of Ets1, as used previously, [47]] specifically interfered with ETS-mediated induction of the promoter and had no effect on activation by Egr2 (data not shown). In contrast, the Nab1 promoter was activated to a lower extent by Ets2 and Etv1, and the ETS factors did not appear to augment activation of the Nab1 promoter by Egr2.

We tested the ability of Ets2 and Etv1 to induce a mutated version of the Nab2 promoter construct containing mutations in two of the Egr2 binding sites (Figure 6C). As observed previously, the mutant promoter is only weakly induced by Egr2. However, Ets2 and Etv1 were nonetheless able to induce this mutant reporter in the absence of Egr2, although the synergistic activation observed with Egr2 was clearly diminished in the mutant promoter.

Ets2 binds to the Nab2 promoter in S16Y Schwann cells

In order to test if ETS factors directly regulate Nab2 in Schwann cells, we carried out ChIP assays in the S16Y Schwann cell line [50], which expresses significant levels of Nab1, Nab2 (data not shown) and ETS factors (Figure 5A). S16Y cells were crosslinked in 1% formaldehyde and sonicated chromatin was immunoprecipitated with either an affinity purified Ets2 antibody (used previously for ChIP analysis, [51]) or an IgG control antibody. Quantitative PCR was carried out on purified DNA with primer sets in the Nab1 and Nab2 promoters, and the IEG2A locus as a negative control. As shown in Figure 7, we observed significant enrichment of Ets2 using two primer sets in the Nab2 promoter, whereas binding of Ets2 was not detected at either the Nab1 promoter or the IEG2A negative control locus. A similar trend in Ets2 occupancy was observed in the S16 Schwann cell line ([50], data not shown).

One limitation of the ChIP assay is that it cannot be used to precisely localize binding of transcription factors. However, the analysis suggests that Ets2 binding is separable from Egr2, because Ets2 binding was not detected using the primer set (#3) that was used previously to detect binding of Egr2 within the Nab2 promoter (Figures 2 and 3). In addition, the relatively simple recognition site of ETS factors (GGAA or GGAT) does not make sequence analysis necessarily predictive, since the upstream cluster of putative ETS binding sites (spanned by primer set 1) does not appear to bind Ets2. Accordingly, deletion of the upstream cluster of putative ETS binding sites does not affect activation of the Nab2 promoter in transfection assays (data not shown). Ets2 binding appears to occur in two separable regions of the Nab2 promoter, as detected by primer sets 2 and 4. Interestingly, primer set 4 overlaps with the corresponding segment of the human NAB2 promoter that was recently shown to be inducible by phorbol ester [39], which also activates ETS proteins. Overall, these data are consistent with regulation of the Nab2 promoter by ETS transactivators in vivo.

Discussion

Recent studies have shown that NAB proteins are required for peripheral nerve myelination by Schwann cells, as mice lacking Nab1/Nab2 displayed a severe congenital hypomyelinating phenotype similar to Egr2 knockout mice [22]. The molecular roles of Egr2 and NAB proteins appear to be closely intertwined at several levels, including both physical interaction and coregulation [2,21-24]. Several previous studies have suggested that EGR factors regulate the expression of Nab1 and Nab2 corepressors. First, Nab2 and, to a lesser extent, Nab1 are activated in a delayed early fashion by a variety of stimuli that induce expression of EGR family members [2,23,39,52,53]. For example, neuregulin treatment of Schwann cells stimulates Egr2 and activates Nab1 and Nab2 expression in a slightly delayed manner [22]. Second, the Nab2 promoter can be activated by EGR factors in transient transfection studies [39], Figure 1, [54]), and ectopic expression of Egr1 and Egr2 stimulates expression of endogenous Nab1 and Nab2 in a variety of cell lines, including Schwann cells [22,36,37,55,56].
These earlier studies, however, did not test direct regulation of NAB corepressors by Egr2. Our data provide several lines of evidence to establish Nab2 regulation by Egr2 in vivo. First, DNAse footprinting analysis identified several Egr2 protected sites in both Nab1 and Nab2 promoters. Second, activation of Nab2 by Egr2 in transient transfection assays was severely compromised when Egr2 binding sites were mutated (Figure 1). Finally, ChIP assays demonstrated direct binding of Egr2 to both promoters in cultured Schwann cells as well as myelinating sciatic nerve (Figures 2 and 3). Several studies have implicated neuregulin signaling as a critical factor in Schwann cell survival and stimulation of myelination [27-34]. Egr2 occupancy at both Nab1 and Nab2 was significantly enhanced upon neuregulin stimulation of Schwann cells. Our results provide the first demonstration of neuregulin-induced binding of a transcription factor to a specific promoter in Schwann cells.

Several groups have shown that Type III neuregulin (membrane-bound) plays a central role in regulating myelination in vivo [29,30,35]. Therefore, addition of soluble neuregulin (as in Figure 2) does not act as a mimic of myelination. Nonetheless, Egr2 is regulated by both soluble neuregulin and interaction with Type III neuregulin [22,57,58], and therefore soluble neuregulin probably induces some of the early pathways relating to Egr2 induction in vivo. Since Egr2 expression is regulated by Type III neuregulin signaling in vivo [58], our ChIP data in myeli-
Whether ETS proteins are involved in regulation of neuregulin signaling [45-47]. Since previous work showed that expression of Nab1 and Nab2 in zebrafish hindbrain is dependent on Egr2 expression [26]. Therefore, it was surprising that Nab2 levels were not affected in Egr2 knockout mice. In contrast, Nab1 levels were significantly lower in the absence of Egr2, even though the Nab1 promoter is less effectively activated by neuregulin and Egr2 expression (Figure 1, [22]). These data suggested that Nab2 might be coregulated by other factors that compensate for loss of Egr2, and promoter analysis revealed several conserved binding sites for ETS transcription factors. ETS family members are activated by neuregulin signaling [45-47]. Since Nab2 is more highly induced by neuregulin stimulation [22], we tested whether ETS proteins are involved in regulation of Nab2.

Both Ets2 and Etv1 activated the Nab2 promoter in transfection assays, and we observed a cooperative effect on the Nab2 promoter when Egr2 was co-expressed together with Ets2 or Etv1. Furthermore, chromatin immunoprecipitation analysis with an Ets2 antibody detected binding in the Nab2 promoter, but not in the Nab1 promoter. Unfortunately, we have been unable to find an Etv1 antibody that is suitable for ChIP analysis, but recent immunohistochemical studies indicate that Etv1/ER81 is expressed in Schwann cells [59]. Based on our data, we propose that the higher induction of Nab2 by neuregulin, compared to Nab1 [22], is due to synergistic activation of the Nab2 promoter by Egr2 and ETS factors. Consequently, the maintained expression of Nab2 levels in the knockout could be mediated by elevated levels of Etv1 (Figure 5), Ets1 [11], or other ETS factors that may be revealed by a more comprehensive analysis of family member expression. In addition, although Ets2 mRNA is not induced in the Egr2 knockout, its activity (as well as that of other ETS factors) could be elevated post-transcriptionally (e.g. phosphorylation).

In contrast, the Nab1 promoter was more modestly activated by ETS proteins, suggesting that Nab1 is more exclusively dependent on EGR factors and consequently is more reduced in the absence of Egr2. However, the modest induction of the Nab1 promoter by ETS factors in transfection assays could reflect some level of regulation of Nab1 expression by ETS proteins in Schwann cells, particularly if there are other ETS binding sites that lie outside of the Nab1 promoter regions we have analyzed. A limitation of these studies is that the importance of the NAB promoters relative to more remote enhancer elements has not been established. The mechanism of Nab2 activation by ETS remains to be determined, since only potential ETS binding sites in the Nab2 promoter have been identified. Despite the commonality of the core ETS motif (GGAa/t), individual ETS factors have distinct binding site preferences. Therefore, future studies will focus on identifying the relevant ETS factor(s) using RNAi approaches and/or knockout mice in order to facilitate such a mechanistic analysis.

Given the in vivo evidence that ETS proteins regulate expression of Egr1 and Egr2 [23,60-62], it seems likely that co-induction of Egr2 and Nab2 by ETS transcription factor activation may have evolved to ensure formation of sufficient Egr2/NAB complexes that are required for specific gene regulation events in Schwann cell differentiation. This may also prevent inappropriate activation of some target genes if Nab2 was not immediately present at the onset of Egr2 induction. Alternatively, it is possible that Nab2 modulates other transcription factors, so that its induction should not exclusively depend on Egr2.

Several groups have proposed that the induction of Nab2 constitutes a negative feedback loop in which EGR activators induce expression of their own corepressor [2,26,39,53]. Our studies refine this model by showing that other neuregulin-regulated pathways direct Nab2 expression. In addition, recent publications have shown that Egr2 is required for certain gene repression mechanisms during myelination [11,12]. Therefore, we suggest that the induction of NAB proteins does not merely con-
stitute a negative feedback loop, but rather, that co-induction of Egr2 and NAB proteins by axon-dependent signals (e.g. neuregulin/erbB) is required to form an Egr2/NAB complex that actively represses transcription of specific genes during peripheral nerve myelination (Figure 8). These results are consistent with our demonstration of direct repression of the Rad gene by an Egr2/NAB complex in Schwann cells [6,22], as well as recent publications implicating repression by the Egr2/NAB complex in macrophages and cardiomyocytes [23,63].

Our studies do not rule out the possibility that other EGR family members and/or other zinc finger proteins may partially compensate in maintaining Nab2 levels in the absence of Egr2. Indeed, previous work has shown that Egr1 and Egr2/Krox20 are coexpressed in Schwann cells at the onset of myelination (P11). In contrast by one month of age, Egr2 is exclusively expressed in myelinating Schwann cells, whereas Egr1 is confined to nonmyelinating Schwann cells [64]. Egr1 is induced ~2-fold in sciatic nerve of mice homozygous for a hypomorphic Egr2 allele [11], and our analysis indicates that Egr1 mRNA is induced about 1.5-fold in the complete absence of Egr2 (data not shown). Importantly, compensation by other Egr family members is not sufficient to maintain Nab1 levels despite the presence of several Egr1 binding sites, and fails to maintain expression of other Egr2 target genes like myelin protein zero, which is reduced up to 50-fold in the Krox20/Egr2 knockout [10-14], suggesting that non-EGR factors contribute significantly to regulation of Nab2 expression. Interestingly, regulation of NAB expression by Egr2 is consistent with previous observations that Nab1 and Nab2 are co-regulated with Egr2 after nerve crush injury [22,36]. However, the decrease in Nab2 expression following nerve injury would be consistent not only with regulation by Egr2, but also by loss of neuregulin-dependent (i.e. axon-dependent) induction of ETS factors, analogous to regulation of ETS factors by neuregulin signaling observed in other systems [44-46].

The involvement of ETS transcription factors in Nab2 regulation resolves several puzzling observations regarding Nab1 and Nab2 activation. First, Nab2 expression is more responsive than Nab1 to several stimuli including serum, neuregulin and NGF [2,22], even though the Nab1 promoter contains more EGR binding sites than Nab2. Second, Nab2 expression is already fairly elevated by E17 in profiling studies of peripheral nerve myelination, even though Egr2 levels do not peak until P10 [49]. Finally, a recent analysis of hematopoietic development showed that expression of the ETS factor, PU.1, induced expression of both Egr2 and Nab2, and the induction of Nab2 was shown to be Egr2-independent [23]. Our analysis of the Nab2 promoter provides a mechanism for Egr2-independent activation of Nab2 by ETS proteins.

**Conclusion**

Our results demonstrate that Egr2 is directly involved in regulation of both Nab1 and Nab2 corepressors, indicating that axon-dependent induction of NAB expression is partially dependent on Egr2. However, the maintained expression of Nab2 in Egr2 deficient mice suggested that other factors could compensate for lack of Egr2. Transfection experiments and chromatin immunoprecipitation assays indicated that Ets2 and Etv1 specifically activate the Nab2 promoter, but not Nab1, which provides an explanation for the differential regulation of NAB corepressors in several developmental systems. Finally, these results suggest that NAB corepressors are not simply feedback inhibitors, but that co-induction of Egr2 with NAB corepressors is critically involved in forming a transcriptional complex required for gene regulation events.

**Methods**

**Promoter Analysis**

Putative Egr2 binding sites were identified by comparison to the previously defined consensus Egr2 binding site [38], and sequence analysis for potential binding sites was performed using the rVISTA program [65]. Footprinting was carried out by incubating 200 ng of purified, FAM-labeled promoter fragments in the presence or absence of recombinant Egr2 protein, and 500 ng of a non-specific 20 bp oligonucleotide in binding buffer (20% glycerol, 20 mM Tris 7.5, 50 mM KCl, 5 mM MgCl2, 0.01 mM ZnCl2,
1 mM DTT, and 0.2 mM PMSF) in a volume of 10 μl. One microliter of 1000 U/ml DNase I (Promega) was added for 1 min at room temperature before adding 90 μl of 0.5% SDS, 100 mM NaCl, and 10 mM EDTA. The resulting fragments were resolved on an ABI Prism 377 Sequencer. Recombinant Egr2 was made by fusing the mouse Egr2 sequence with the 6 × His tag in pET30a (Novagen), and purifying the protein from bacteria using Ni-NTA agarose (Qiagen) according to the manufacturer’s protocol.

**Plasmids**
A 370 bp NotI/PvuII fragment of the mouse Nab1 promoter (-250 to +120 relative to the transcription start site) and a 1000 bp KpnI/Smal fragment of the mouse Nab2 promoter (-850 to +150) were fused to the luciferase gene in the pGL3 vector (Promega). The two upstream Egr2 binding sites in the Nab2 promoter were destroyed by replacing C residues at positions 2 and 8 with G. The Etv1 (ER81) expression plasmid was provided by Ralf Janknecht. The expression construct for Egr2 has been previously described [4]. A mouse Ets2 expression plasmid was provided by Barbara Graves [66].

**Cell culture conditions and transfection assays**
JEG3 cells (a trophoblast-derived cell line) were transfected as described [43,54]. The average luciferase activity of each sample was normalized to the β-galactosidase activity from the transfected lacZ reporter. Unless otherwise indicated, means and standard deviations of two separate transfections are shown. The S16Y rat Schwann cell line [50] was maintained in DMEM (Dulbecco’s Modified Eagle’s Medium) supplemented with 10% bovine growth serum (Hyclone). Primary rat Schwann cells were cultured in N2 medium for 24 hours [36]. The cells were treated with 20 ng/ml neuregulin-1 β isoform (heregulin-β 1, R&D Systems) for 2 h prior to cross-linking cells with 1% formaldehyde. Cross-linked cells were sonicated in a Biorupter sonicator (Diagenode) for 20 minutes.

For each immunoprecipitation, 300 μg of sonicated chromatin (as determined by Bio-Rad protein assay) from either nerves or cells was combined with Egr2 antibody (Covance) or rabbit IgG control antibody (Upstate) overnight at 4°C. 10% of this amount was saved as input. Chromatin-antibody complexes were collected with 30 μl of protein G sepharose (pre-blocked with herring sperm DNA and Bovine serum albumin) for 1 hour at 4°C. Beads were washed with low salt, high salt and lithium chloride buffers as described [14,41]. Crosslinks were reversed for 5 h at 65°C in buffer containing 1% SDS, 0.1 M NaHCO3 and 200 mM NaCl and DNA was purified using QIAquick PCR purification kit (Qiagen). Quantitative PCR was carried out on the purified samples in duplicate with primers specific to regions of interest. Percentage recovery relative to input DNA was determined using the Comparative Ct method [68]. ChiP analysis in the S16Y Schwann cell line [50] was performed similarly with an affinity purified Ets2 antibody [51].

**Expression analysis**
Sciatic nerve cDNA from pooled (or individual) Egr2 wild type, heterozygous and homozygous littersmates at day P7 was provided by Lawrence Wrabetz and analyzed as described [14,41,43]. Quantitative RT-PCR was performed by monitoring in real-time the increase in fluorescence of the SYBR-GREEN dye [67] using the TaqMan 7000 Sequence Detection System (Applied Biosystems). Relative amounts of each gene between samples were determined using the Comparative Ct method [68] and normalized to the relative levels of 18S rRNA.

**Chromatin immunoprecipitation (ChiP) assays**
All experiments were performed in strict accordance with experimental protocols approved by the University of Wisconsin, School of Veterinary Medicine. ChiP analysis of myelinating rat sciatic nerve at postnatal day 10 was performed as described [14,41], by mincing pooled sciatic nerves from 8–13 rat pups in 1% formaldehyde for 25 min. For neuregulin stimulation, primary rat Schwann cells were washed once in serum-free media and cultured in N2 medium for 24 hours [36]. The cells were treated with 20 ng/ml neuregulin-1 β isoform (heregulin-β 1, R&D Systems) for 2 h prior to cross-linking cells with 1% formaldehyde. Cross-linked cells were sonicated in a Biorupter sonicator (Diagenode) for 20 minutes.

For each immunoprecipitation, 300 μg of sonicated chromatin (as determined by Bio-Rad protein assay) from either nerves or cells was combined with Egr2 antibody (Covance) or rabbit IgG control antibody (Upstate) overnight at 4°C. 10% of this amount was saved as input. Chromatin-antibody complexes were collected with 30 μl of protein G sepharose (pre-blocked with herring sperm DNA and Bovine serum albumin) for 1 hour at 4°C. Beads were washed with low salt, high salt and lithium chloride buffers as described [14,41]. Crosslinks were reversed for 5 h at 65°C in buffer containing 1% SDS, 0.1 M NaHCO3 and 200 mM NaCl and DNA was purified using QIAquick PCR purification kit (Qiagen). Quantitative PCR was carried out on the purified samples in duplicate with primers specific to regions of interest. Percentage recovery relative to input DNA was determined using the Comparative Ct method [68]. ChiP analysis in the S16Y Schwann cell line [50] was performed similarly with an affinity purified Ets2 antibody [51].

**Immunoblotting analysis**
Sciatic nerves were dissected from Sprague-Dawley rat pups at postnatal day 5 (P5) and day 15 (P15) and homogenized in buffer containing 300 mM NaCl, 50 mM Tris pH 7.5, 1% Triton X-100, 10 mM EDTA pH 8.0, 1 μg/ml of pepstatinA, 1 μg/ml Leupeptin and 0.1 mM phe-
nethylmethylsulfonlfyl fluoride. The lysates were then analyzed by immunoblotting with Ets2 [51], Egr2 (Covance) or ETV1/ER81 (Santa Cruz, CA) antibody as indicated in figures. The membranes were reprobed with β-Actin (IL-20, Developmental Studies Hybridioma Bank at University of Iowa) for loading control. The membranes were probed with horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibody (Jackson Laboratories, Bar Harbor, ME, USA). Luminescence was detected with West pico or west dura chemiluminescence detection system (Pierce, Rockford, IL, USA).

List of abbreviations
EGR (early growth response) ChIP (chromatin immunoprecipitation), IMG2a (immunoglobulin G 2a), CMT (Charcot-Marie Tooth)

Authors’ contributions
RS performed transfections, immunoblotting and ChIP experiments and helped write the manuscript. SJ assisted in development of in vivo ChIP assays and contributed preliminary data. RW performed DNase I footprinting. SS and TE produced and purified anti-Ets2 sera for ChIP analysis. JS was responsible for experimental design and analysis and drafted this manuscript. All authors read and approved the final manuscript.

Acknowledgements
We thank Lawrence Wrabetz for generously providing sciatic nerve RNA from Krox20 null animals and Richard Quares for providing the S16Y cell line. We would also like to thank Ralf Janknecht and Barbara Graves for providing the Etv1 and Ets2 expression plasmids, respectively, David Jarrard for help with analysis and David Hitt for help with preliminary data. RW performed DNase I footprinting. SS and TE produced and purified anti-Ets2 sera for ChIP analysis. JS was responsible for experimental design and analysis and drafted this manuscript. All authors read and approved the final manuscript.

References
1. Russo MW, Sevetson BR, Milbrandt J: Identification of NAB1, a repressor of NGFI-A- and Krox20-mediated transcription. Proc Natl Acad Sci U S A 1995, 92(15):6873-6877.
2. Svenonius K, Sevetson BR, Apel ED, Zimonjic DB, Popescu NC, Milbrandt J: NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli. Mol Cell Biol 1996, 16(7):3545-3553.
3. Svenonius K, Sevetson BR, Golda T, Stanton JJ, Swirnoff AH, Milbrandt J: Novel mutants of NAB corepressors enhance activation by Egr transactivators. EMBO J 1998, 17(20):6010-6019.
4. Sevetson BR, Svenonius K, Milbrandt J: A novel activation function for NAB proteins in EGR-dependent transcription of the luteinizing hormone beta gene. J Biol Chem 2000, 275(24):19794-19797.
5. Abdulkadir SA, Qu Z, Garabedian E, Song SK, Peters T, Svenonius K, Carbogni JM, Naughton CK, Catalano V, Ackerman J, Gordon JL, Humphrey PA, Milbrandt J: Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med 2001, 7(1):101-107.
6. Srivinasan R, Mager GM, Ward RM, Mayer J, Svenonius K: NAB2 represses transcription by interacting with the CHD4 subunit of the NuRD complex. J Biol Chem 2006, 281(15):13129-13137.
7. Schneider-Maunoury S, Topilko P, Sevetson BR, Golda T, Stanton JJ, Swirnoff AH, Milbrandt J, Svenonius K, Mournoud M, Pournim S, Babinet C, Charnay P: Disruption of Krox-20 results in alteration of rhombomeres 3 and 5 in the developing hindbrain. Cell 1993, 75:1199-1214.
8. Swiatek P, Gridley T: Perinatal lethality and defects in hindbrain development in mice homozygous for a targeted mutation of the zinc finger gene Krox20. Genes and Development 1993, 7:2071-2084.
9. Levi G, Topilko P, Schneider-Maunoury S, Lasagna L, Mantero S, Cancedda R, Charnay P: Defective bone formation in Krox20 mutant mice. Development 1996, 122:131-140.
10. Topilko P, Schneider-Maunoury S, Levi G, Baron-Van Evercooren A, Chennoufi AB, Sevetson BR, Babinet C, Charnay P: Krox-20 controls myelination in the peripheral nervous system. Nature 1994, 371:796-799.
11. Le N, Nagarajan R, Wang JY, Araki T, Schmidt RE, Milbrandt J: Analysis of congenital hypomyelinating Egr2Lo/Lo nerves identifies Sox2 as an inhibitor of Schwann cell differentiation and myelination. Proc Natl Acad Sci U S A 2005, 102(7):2596-2601.
12. Decker L, Desmarquet-Trin-Dinh C, Taillebour E, Ghislan J, Vallat JF, Charnay P: Peripheral myelin maintenance is a dynamic process requiring a constitutive Krox-20 expression. J Neurosci 2006, 26(38):9771-9779.
13. Zorick TS, Syroid DE, Brown A, Gridley T, Lemke G: Krox-20 controls SCIP expression, cell cycle exit and susceptibility to apoptosis in developing myelinating Schwann cells. Development 1999, 126(7):1397-1406.
14. LeBlanc SE, Jang SW, Ward RM, Wrabetz L, Svenonius K: Direct Regulation of Myelin Protein Zero Expression by the Egr2 Transactivator. J Biol Chem 2006, 281:5453-5460.
15. LeBlanc SE, Ward RM, Svenonius K: Neuropathy-associated Egr2 mutations disrupt cooperative activation of myelin protein zero by Egr2 and Sox10. Mol Cell Biol 2007, 27(9):3521-3529.
16. Warner LE, Mancias P, Butler LJ, McDonald CM, Keppen L, Koob KG, Lupski JR: Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelopathies. Nat Genet 1998, 18(4):382-384.
17. Timmerman V, De Jonghe P, Ceuterick C, De Vriendt E, Lofgren A, Nels E, Warner LE, Lupski JR, Martin JJ, Van Broeckhoven C: Novel missense mutation in the early growth response 2 gene associated with Dejerine-Sottas syndrome phenotype. Neurology 1999, 52(9):1827-1832.
18. Bellone E, Di Maria E, Soriani S, Varesio L, Doria LL, Ajmar F, Mandich P: A novel mutation (D305V) in the early growth response 2 (EGR2) gene in a severe Charcot-Marie-Tooth type 1 disease. Hum Mutat 1999, 14(4):253-254.
19. Pareyson D, Taroni F, Botin S, Morbin M, Baratta S, Lauria G, Ciano C, Ghirlanda Z: Cranial nerve involvement in CMT disease type 1 due to early growth response 2 gene mutation. Neurology 2006, 54(8):1696-1698.
20. Mikeseva E, Huhne K, Raunenstrauss B, Mazanek R, Barankova L, Vyhnaele M, Horacek O, Seeman P: Novel EGR2 mutation R359Q is associated with CMT type 1 and progressive scoliosis. Neurological Disease 2005, 15(11):764-767.
21. Warner LE, Svenonius K, Milbrandt J, Lupski JR: Functional consequences of mutations in the early growth response 2 (EGR2) correlate with severity of human myelinopathies. Hum Mol Genet 1999, 8(7):1245-1251.
22. Le N, Nagarajan R, Wang JY, Svenonius K, LaPash C, Araki T, Schmidt RE, Milbrandt J: NAB proteins are essential for peripheral nervous system myelination. Nat Neurosci 2005, 8(7):932-940.
23. Laslo P, Spooner CJ, Warmflash A, Lancki DW, Lee HJ, Sciammas R, Ganttner BN, Warmflash A: Novel EGR2 mutation R359Q is associated with CMT type 1 and progressive scoliosis. Neurological Disease 2005, 15(11):764-767.
24. Buitrago M, Lorenz K, Maass AH, Oberdorf-Maass S, Keller U, Schneidereit EM, Ivashchenko Y, Lohse MJ, Engelhardt S: The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy. Nat Med 2005, 11(8):837-844.
25. Abdulkadir SA, Carbone JM, Naughton CK, Humphrey PA, Catalano WJ, Milbrandt J: Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma. Hum Pathol 2001, 32(9):935-939.
26. Mechtchi-Grigorou F, Garel S, Charnay P: NAB proteins mediate a negative feedback loop controlling Krox-20 activity in the developing hindbrain. Development 2000, 127:119-129.
27. Riethmacher D, Sonnenberg-Riethmacher E, Brinkmann Y, Yamaai T, Lewin GR, Birchmeier C: Severe neuropathies in mice with tar-
geted mutations in the ErbB3 receptor. Nature 1997, 389(6652):725-730.

18. Mariani J, Answers O, Topilko P, Charnay P, Birnmeir C: A dual role of erbB2 in myelination and in expansion of the schwann cell precursor pool. J Cell Biol 2000, 148(5):1035-1046.

19. Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birnmeir C, Role L, Lai C, Schwab MH, Nave KA: Axonal neurogulin-1 regulates myelin sheath thickness. Science 2004, 304(5671):700-703.

20. Taveggia C, Zanazzi G, Petrylak A, Yano H, Rosenbluth J, Einheber S, Xu X, Esper RM, Loeb JA, Shrager P, Chao MV, Falls DL, Role L, Salzer JL. Neuregulin-1 type III determines the ensheathment fate of Schwann cells. Neuron 2005, 47(5):681-694.

21. Maurel P, Salzer JL: Axonal regulation of Schwann cell proliferation and survival and the initial events of myelination requires PI 3-kinase activity. J Neurosci 2000, 20(12):6455-6465.

22. Jang SW, Tennekoon GL, Birnbaum M, Marchionni MA, Rutkowski JL: Molecular mechanisms for development and maintenance of a P13K/Akt/Bad pathway in Schwann cell survival. Mol Cell Neurosci 2001, 17(4):761-767.

23. Ogata T, Iijima S, Hoshikawa S, Miura T, Yamamoto S, Oda H, Nakamura K, Tanaka S: Opposing extracellular signal-regulated kinase and Akt pathways control Schwann cell myelination. J Cell Biol 2000, 149(4):627-637.

24. Chen S, Velarde MO, Varot A, Yu ZZ, Miller SJ, Coss D, Corfas G: Neuregulin I-erbB signaling is necessary for normal myelination and sensory function. J Neurosci 2006, 26(12):3079-3086.

25. Nave KA, Salzer JL: Axonal regulation of myelination by neuroglin-1. J Dev Biol 2001, 109:249-255.

26. Nagarajan R, Saven J, Le N, Oka M, Marlbndt HA, Davidson N: Modulation of early growth response (EGR) transcription factor-dependent gene expression by using recombinant adenosine. Gene 2000, 258(1-2):63-69.

27. Fu M, Zhu X, Zhang J, Liang J, Lin Y, Zhao L, Ehrengruber MU, Chen YE. Egr-1 target genes in human endothelial cells identified by microarray analysis. Gene 2003, 315:33-41.

28. Murphy P, Topilko P, Schneider-Maunoury S, Seitanidou T, Baran-Van Evercooren A, Charnay P. The regulation of Krox-20 expression reveals important steps in the control of peripheral glial cell development. Dev Biol 1996, 122(9):2847-2857.

29. Taveggia C, Pizzagalli A, Fagianl E, Mesling A, Fcetia ML, Wrabetz L: Characterization of a Schwann cell enhancer in the myelin basic protein gene. J Neurochem 2004, 91(4):813-824.

30. Sedy J, Tseng S, Walro JM, Grim M, Kucera J: EGR-1: role in development. J Cell Biol 2005, 169(2):2663-2674.

31. Morrison TB, Weis JJ, Wittwer CT: Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques 1998, 24(6):954-962.

32. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408.